FDA releases FAQs on remdesivir EUA, antibody tests
The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients.
The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.
FDA this week also posted a patient-and-consumer-focused FAQ about SARS-CoV-2 antibody, or serology, testing, including a guide to understanding test results and where to obtain them.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…